



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

April 01, 2008 6:30 – 9:00 p.m. **PLEASE NOTE DATE**

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**
(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:20**
 - Clinical Programs Update
 - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:20 - 7:30**
 - Cough and Cold Products in Children < 2 years old
 - Desmopressin (DDAVP) Spray
 - Erythropoiesis Stimulating Agents
 - Zetia[®]/Vytorin[®]
- 6. Clinical Update: Drug Reviews** **7:30 – 8:00**
(Public comment prior to Board action)
 - Astelin[®] (azelastine) Nasal Spray
 - Azor[®] (amlodipine/olmesartan)
 - Perforomist[®] (formoterol)
 - Xyzal[®] (levocetirizine)
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **8:00 – 8:20**
(Public comment prior to Board action)
 - Ophthalmics: Antihistamines (including Pataday[®] (olopatadine 0.2%))
 - Remicade[®] in Crohn's
 - Welchol[®] – new indication for improvement in glycemic control
- 8. Drug Classes – New** **8:20 – 8:20**
 - No new drug classes
- 9. RetroDUR** **8:20 - 8:30**
 - Botulinum Toxin (including FDA alert)
- 10. New Drug Product Plan Exclusions (Consent Agenda Topic)** **8:30 - 8:35**

11. Updated New-to-Market Drug Monitoring Log **8:35 - 8:40**

12. General Announcements **8:40 - 9:00**

FDA Safety Alerts

- Fentanyl Patches – leaks
- Avandia[®] – new medication guide
- Tysabri[®] – liver injury
- Spiriva[®]/Foradil[®] – correct use of powder capsules
- Spiriva[®] – increased stroke risk
- Tamiflu[®] – neuropsychiatric events
- Tussionex[®] – life-threatening adverse events
- Prezista[®] – hepatotoxicity

13. Adjourn **9:00**